ClinicaliQ Trial Snapshot
- Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — Recruiting • Phase II • Oncology • NCT07096778.
- Inobrodib combined with pomalidomide and dexamethasone shows promise in treating multiple myeloma that resists standard therapies.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines. Conditions: Multiple Myeloma Refractory, Multiple Myeloma in Relapse Interventions: Inobrodib, Pomalidomide,…